Nivolumab, approved for adjuvant therapy in resected esophageal cancer, is typically administered at 240 mg every 2 weeks (Q2W) or 480 mg every 4 weeks (Q4W). However, data on the 480 mg Q4W regimen ...

Patients were sequentially assigned to receive zanzalintinib 100 mg orally once daily plus nivolumab 480 mg intravenously (IV) once every 4 weeks or zanzalintinib 100 mg orally once daily plus ...

The benefit of nivolumab on DFS was present in all-comers, and centrally assessed PD-L1 expression using the combined positive score was not a strong predictor of nivolumab efficacy.

There were 668 patients who were enrolled in the study who were randomly assigned to either receive 1-mg/kg nivolumab plus 3-mg/kg ipilimumab with 480-mg nivolumab every 4 weeks for up to 2 years ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

Patients received nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) every 3 weeks for 4 cycles, followed by nivolumab (480 mg) every 4 weeks for up to 2 years.

The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally advanced squamous cell carcinoma of the head and neck. "This is the ...

Opdivo is a prescription drug used to treat certain types of cancer. Learn about the drug’s dosages, form, strengths, and more.

And the nivolumab monotherapy arm received nivolumab 240 mg every 2 weeks for six doses, followed by nivolumab 480 mg every 4 weeks.

The recommended nivolumab dose for patients weighing 40 kg or more is 480 mg every 4 weeks or 240 mg every 2 weeks until disease recurrence or unacceptable toxicity for up to 1 year.